Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort.
about
Circulating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort.The RANK/RANKL/OPG system in tumorigenesis and metastasis of cancer stem cell: potential targets for anticancer therapy.Increased breast tissue receptor activator of nuclear factor-κB ligand (RANKL) gene expression is associated with higher mammographic density in premenopausal women.
P2860
Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Osteoprotegerin and breast can ...... trol study in the EPIC cohort.
@ast
Osteoprotegerin and breast can ...... trol study in the EPIC cohort.
@en
type
label
Osteoprotegerin and breast can ...... trol study in the EPIC cohort.
@ast
Osteoprotegerin and breast can ...... trol study in the EPIC cohort.
@en
prefLabel
Osteoprotegerin and breast can ...... trol study in the EPIC cohort.
@ast
Osteoprotegerin and breast can ...... trol study in the EPIC cohort.
@en
P2093
P2860
P50
P1433
P1476
Osteoprotegerin and breast can ...... trol study in the EPIC cohort.
@en
P2093
Amalia Mattiello
Androniki Naska
Aurélie Affret
Carla H Van Gils
Helena Schock
J Ramón Quirós
Laure Dossus
Marc Gunter
María-Dolores Chirlaque
Mathilde His
P2860
P2888
P356
10.1186/S12916-017-0786-8
P407
P50
P577
2017-02-08T00:00:00Z
P6179
1083508265